Domain Therapeutics

Domain Therapeutics SA, with communications datelined Strasbourg, France, Montreal, Canada and Boston, United States, describes itself as a clinical-stage company with over two decades of work on G protein-coupled receptors (GPCRs), focused on immuno-oncology and inflammation. Its anti-CCR8 monoclonal antibody DT-7012 is designed to deplete regulatory T cells inside tumours; the DOMISOL phase 1/2 trial (NCT06819735), sponsored by its subsidiary Domain Therapeutics Australia Pty Ltd, tests it alone and with an immune checkpoint inhibitor in selected advanced solid tumours, with first patients dosed in Australia in October 2025. A separate investigator-sponsored phase 1 trial of DT-7012 in relapsed or refractory cutaneous T-cell lymphoma (NCT07213882) is led by Assistance Publique, Hopitaux de Paris. Other programmes include DT-9081, an EP4 receptor antagonist that entered a phase 1 trial in solid tumours in 2022 (NCT05582850), and DT-9046, a biased PAR2 antagonist for inflammatory disease. The parent company's first registered cancer trial, NCT05582850, was posted on ClinicalTrials.gov in October 2022; the Australian subsidiary's first, NCT06819735, was posted in February 2025.